Welcome to our dedicated page for Claritev news (Ticker: CTEV), a resource for investors and traders seeking the latest updates and insights on Claritev stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Claritev's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Claritev's position in the market.
Claritev (NYSE: CTEV) has announced two key appointments to strengthen its leadership team as part of its business transformation strategy. Dr. Jigar S. Patel will join as Chief Medical Officer effective April 14, 2025, bringing over 18 years of experience from Cerner/Oracle. He will provide medical guidance on strategic development and product innovation of Claritev's healthcare technology solutions.
Dr. Fernando Schwartz has been appointed as Chief Artificial Intelligence Officer, effective February 17, 2025. With 15 years of leadership in data science and machine learning, Schwartz previously served as VP of AI at ADP and led global data science strategy at Merck's Human Health Division. He will lead the company's AI and analytics strategy under Chief Digital Officer Michael Kim.
Claritev (NYSE: CTEV) announced that its data solution Ceres® has won the 'Data Solution of the Year for Insurance' award in the 6th annual Data Breakthrough Awards' Industry Applications Category. Ceres is designed to help supplemental carriers and benefits brokers provide unbiased benefit recommendations.
The platform leverages AI-powered insights and de-identified claims data from over a million members to transform supplemental plan design from an intuition-based process into a data-driven approach. The solution enables modeling of different census scenarios to determine which benefits provide the highest value through predicted utilization and payout amounts, benchmarked against similar employer groups.
According to Travis Dalton, Chairman, CEO and President of Claritev, Ceres exemplifies their philosophy that data and technology should empower rather than replace people. The platform aims to shift focus from lowest-cost offerings to high-value, population-specific plans.
Claritev (NYSE: CTEV) has scheduled its first quarter 2025 earnings conference call for Thursday, May 8, 2025, at 8:00 am Eastern Time. The company will release its Q1 2025 financial results the same day.
Participants can pre-register for the call through a provided link, after which they will receive a calendar invitation with access details and a unique PIN. A live webcast will be accessible through the company's Investor Relations website at investors.claritev.com/events-and-presentations, with participants advised to join ten minutes before the start time.
The earnings press release and supplemental slide deck will be available on the company website. For those unable to attend live, a replay will be available approximately two hours after the call through the archived webcast. Operator assistance is available at (404) 975-4839 or (833) 470-1428 with access code 685315.
Claritev (NYSE: CTEV), a healthcare technology company, has announced a sponsorship agreement with professional golfer Neal Shipley. As part of the deal, Shipley will display the Claritev logo on his shirt collar during competitions.
Shipley, 24, turned professional in summer 2024 following a notable amateur career where he made history as the low amateur at both the 2024 Masters Tournament and U.S. Open - becoming the ninth golfer in PGA TOUR history to achieve this distinction in the same year. He currently competes on the PGA TOUR Americas and has received sponsor exemptions for multiple PGA TOUR events.
The rising golf star was recently featured in the third season of Netflix's docuseries Full Swing, which captured his journey to the 2024 Masters and his experience playing alongside Tiger Woods in the final round.
ClearNote Health has announced a new agreement with Claritev (NYSE: CTEV) to make its Avantect® Pancreatic Cancer Test available through Claritev's national PHCS and MultiPlan Networks. The test is a DNA-based blood screening that combines epigenomic and genomic signals with machine learning to detect early pancreatic cancer indicators.
The Avantect test specifically targets high-risk patients, including:
- Type 2 diabetes patients aged 50 and older
- Individuals with relevant family history
- People with genetic predisposition
The test utilizes 5-hydroxymethylcytosine (5hmC) profiling in cell-free DNA and AI algorithms to detect tumor development earlier than conventional methods. This is particularly significant as pancreatic cancer often has only a 3% five-year survival rate when diagnosed at advanced stages.
FAQ
What is the current stock price of Claritev (CTEV)?
What is the market cap of Claritev (CTEV)?
